Reporting of transactions in Orphazyme’s shares
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached information of transactions in Orphazyme’s shares by a person closely associated with a person discharging managerial responsibilities in Orphazyme pursuant to Article 19 of the Market Abuse Regulation.
Reporting of transactions in Orphazymes shares
Notification Orpha pooling person closely associated ...
Read moreMajor shareholder announcement
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached major shareholder notifications pursuant to Section 38 of the Danish Capital Markets Act.
Major shareholder letter to Orphazyme
Major shareholder letter to Orphazyme as Novo Nordisk fonden
Major shareholder announcement
Read moreOrphazyme initiates directed issue and private placement of shares
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Board of Directors has resolved to initiate a directed issue and private placement of up to an aggregate of 7,032,937 new shares and existing shares, at market price as determined by the Board of Directors of the Company through a book-building process, corresponding to approximately 35.16% of the Company’s currently registered share capital.
Orphazyme initiates directed issue and private place
Read morePreliminary results for 2019 and financial outlook for 2020
Feb 4, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today releases preliminary results for 2019 as well as the financial outlook for 2020.
Preliminary results for 2019 and financial outlook
Read moreCapital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Jan 31, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today decided on a capital increase as a result of a directed issue of bonus shares to Kansas Life Sciences Development Company, Inc. (“KLSDC”) and UCL Business Ltd. (“UCLB”). The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association.
Capital increase of 20650 shares in Orphazyme
Read moreResolutions passed at the Extraordinary General Meeting in Orphazyme A/S
Jan 25, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the shareholders passed the following resolutions.
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jan 7, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreOrphazyme announces US Early Access Program for Niemann-Pick disease Type C
Jan 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the availability of an Early Access Program (EAP) in the United States (US) for its investigational drug arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Orphazyme announces early access program
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S - CORRECTION
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.
Notice to convene EGM correction
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S
Jan 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.
Read more